收费全文 | 14621篇 |
免费 | 1024篇 |
国内免费 | 86篇 |
耳鼻咽喉 | 90篇 |
儿科学 | 464篇 |
妇产科学 | 396篇 |
基础医学 | 1771篇 |
口腔科学 | 422篇 |
临床医学 | 1927篇 |
内科学 | 2205篇 |
皮肤病学 | 205篇 |
神经病学 | 1380篇 |
特种医学 | 486篇 |
外科学 | 1707篇 |
综合类 | 256篇 |
一般理论 | 19篇 |
预防医学 | 1751篇 |
眼科学 | 159篇 |
药学 | 1114篇 |
中国医学 | 16篇 |
肿瘤学 | 1363篇 |
2023年 | 65篇 |
2022年 | 103篇 |
2021年 | 200篇 |
2020年 | 123篇 |
2019年 | 231篇 |
2018年 | 263篇 |
2017年 | 210篇 |
2016年 | 232篇 |
2015年 | 259篇 |
2014年 | 403篇 |
2013年 | 556篇 |
2012年 | 827篇 |
2011年 | 883篇 |
2010年 | 547篇 |
2009年 | 415篇 |
2008年 | 840篇 |
2007年 | 862篇 |
2006年 | 874篇 |
2005年 | 815篇 |
2004年 | 823篇 |
2003年 | 771篇 |
2002年 | 782篇 |
2001年 | 354篇 |
2000年 | 371篇 |
1999年 | 329篇 |
1998年 | 173篇 |
1997年 | 159篇 |
1996年 | 121篇 |
1995年 | 137篇 |
1994年 | 128篇 |
1993年 | 91篇 |
1992年 | 250篇 |
1991年 | 210篇 |
1990年 | 184篇 |
1989年 | 168篇 |
1988年 | 154篇 |
1987年 | 175篇 |
1986年 | 156篇 |
1985年 | 155篇 |
1984年 | 99篇 |
1983年 | 111篇 |
1982年 | 65篇 |
1981年 | 74篇 |
1979年 | 84篇 |
1978年 | 84篇 |
1977年 | 65篇 |
1974年 | 86篇 |
1973年 | 62篇 |
1972年 | 64篇 |
1971年 | 66篇 |
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献Areas covered: Approximately 10–45% of patients undergoing head-and-neck cancers surgery develop SSIs. SSIs can lead to delayed wound healing, increased morbidity and mortality as well as costs. Consequently, SSIs need to be avoided where possible, as even the surgery itself impacts on patients’ subsequent activities and their quality of life, which is exacerbated by SSIs. Several risk factors for SSIs need to be considered to reduce future rates, and care is also needed in the selection and duration of antibiotic prophylaxis.
Expert commentary: Head and neck surgeons should give personalized care especially to patients at high risk of SSIs. Such patients include those who have had chemoradiotherapy and need reconstructive surgery, and patients from lower and middle-income countries and from poorer communities in high income countries, who often have high levels of co-morbidity because of resource constraints. 相似文献